Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials
Main Authors: | McNeil Ngongondo, Justin Ritz, Michael D. Hughes, Mitch Matoga, Mina C. Hosseinipour |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLOS Global Public Health |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10766173/?tool=EBI |
Similar Items
-
Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.
by: McNeil Ngongondo, et al.
Published: (2024-01-01) -
The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01) -
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
by: Yim HJ, et al.
Published: (2022-09-01) -
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023-06-01) -
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study
by: Giacomo Stroffolini, et al.
Published: (2024-02-01)